Table 2: Studies proving the usefulness of performing PETCT scan on patients during followup with rising tumor markers for the detection of cancer lesions undetectable by conventional morphological imaging.

Study/yearResultsRemarksTumor markers Reference

Filippi et al. Nucl Med Commun. 2011 FDG PETCT was positive in 36 out of 46 patients with rising biomarkers The FDG-PET/CT scan plays an important role in restaging breast cancer patients with rising tumor markers and negative or equivocal findings in conventional imaging techniquesCEA and CA15-3[58]

Evangelista et al. Eur J Nucl Med Mol Imaging. 2011PETCT scan analysis was positive in 30 out of 40 patients with elevated tumor marker FDG PETCT is more sensitive than CT for the evaluation of disease relapse; PETCT might be considered a complementary imaging technique during followup in patients with breast cancerCA15-3[59]

Champion et al. Cancer 2011PETCT scans were positive in 181 patients (79.5%) and normal in 47 patients with rising CA15-3 and/or CEAFDG PETCT imaging is an efficient technique to detect breast cancer recurrence suspected on tumor marker rising in asymptomatic patientsCEA and CA15-3[60]

Grassetto et al. Eur J Radiol. 2011 Tumor deposits were detected in 40/89 patients by FDG PETCTFDG PETCT may have a potential role in asymptomatic patients with rising markers and negative conventional imaging CA15-3[61]

Katayama et al. Ann Nucl Med. 2012PETCT scan analysis was positive in 23 out of 47 patients with elevated tumor marker The change in the tumor marker levels was substantially correlated with the PET findings and moderately correlated with the CT findingsCEA, I-CTP, CA15-3, BCA225, and NCC-ST-439[62]